Fig. 3.
Ga68-PSMA PET-CT maximum intensity projection (a, b) and sagittal (c, d) images. Pre (a, c) and 8 weeks post (b, d) Lu-177-PSMA therapy, images showed molecular progressive disease (new PSMA avid lesions and increase extent of previous lesions). This 69 years old prostate cancer patient earlier treated with multiple lines of anti-androgens and docetaxel chemotherapy. Pre and 8 weeks post Lu-177-PSMA therapy, PSA showed progressive disease (277 ng/ml vs 400 ng/ml)
